A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2018
At a glance
- Drugs AZD-1775 (Primary)
- Indications Advanced breast cancer; Fallopian tube cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 28 Mar 2018 Status changed from active, no longer recruiting to completed.
- 06 Dec 2017 Planned End Date changed from 31 Aug 2017 to 11 Dec 2017.
- 06 Dec 2017 Planned primary completion date changed from 31 Aug 2017 to 11 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History